Minerva Neurosciences (NERV) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Minerva Neurosciences (NERV) Annonuces Significant Top-Line Data from MDD with MIN-202 Phase 1b
March 11, 2016 8:33 AM ESTMinerva Neurosciences, Inc. (NASDAQ: NERV) announced positive top line results from a Phase Ib clinical trial in major depressive disorder (MDD) with MIN-202 (JNJ-42847922), a selective orexin-2 receptor antagonist under joint development with Janssen Pharmaceutica NV.
Treatment with MIN-202 was observed to result in consistent improvements in the symptoms of depression in MDD patients in this trial, said Dr. Remy Luthringer, president and chief executive officer of Minerva. The results pave the way to initiate a Phase IIb trial in patients suffering from MDD. These improvements support the potential of MIN-202 to have a... More
